Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Correction

The role of GLP-1 receptor agonists in managing type 2 diabetes

Cleveland Clinic Journal of Medicine October 2022, 89 (10) 597;
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

    • View popup
    TABLE 1

    Glucagon-like peptide-1 receptor agonists approved for use in the United States

    DrugAvailable dosesFrequency and routeDose approved for weight management
    Exenatide5 μg, 10 μgTwice daily subcutaneouslyNot approved
    Liraglutide0.6 mg, 1.2 mg, 1.8 mgOnce daily subcutaneously0.6 mg once daily for 1 week, increase by 0.6 mg daily at weekly intervals to a target dose of 3 mg once daily
    Exenatide extended-release2 mgOnce weekly subcutaneouslyNot approved
    Dulaglutide0.75 mg, 1.5 mg, 3 mg, 4.5 mgOnce weekly subcutaneouslyNot approved
    Semaglutide0.25 mg, 0.5 mg, 1 mg, 2 mgOnce weeklyTitrate every 4 weeks:
    0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg once weekly
    Semaglutide, oral3 mg, 7 mg, 14 mgOnce daily by mouthNot approved
    Liraglutide-insulin degludec0.36 mg-10 U
    0.5 mg-16 U
    Once daily subcutaneouslyNot approved
    Lixisenatide-insulin glargine5 μg-15 U
    10 μg-30 U
    Once daily subcutaneouslyNot approved
    Tirzepatide2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mgOnce weekly subcutaneouslyNot approved
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 89 (10)
Cleveland Clinic Journal of Medicine
Vol. 89, Issue 10
1 Oct 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The role of GLP-1 receptor agonists in managing type 2 diabetes
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The role of GLP-1 receptor agonists in managing type 2 diabetes
Cleveland Clinic Journal of Medicine Oct 2022, 89 (10) 597;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The role of GLP-1 receptor agonists in managing type 2 diabetes
Cleveland Clinic Journal of Medicine Oct 2022, 89 (10) 597;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • The role of GLP-1 receptor agonists in managing type 2 diabetes
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Treatment of H pylori infection
  • When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
Show more Correction

Similar Articles

Subjects

  • Diabetes
  • Endocrinology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire